For adults with recurrent (repeated) C. diff infection

Find a Study Site

Have you experienced recurrent C. diff infection?

The PRISM4 study is testing a new investigational therapy called CP101.
In a recent study, participants with recurrent C. diff who received CP101 after completing a round of antibiotics were significantly less likely to experience another episode of C. diff, compared to participants who received antibiotics alone. In the study, 74.5% of participants who received CP101 achieved a clinical cure, meaning they did not experience a recurrence of C. diff within 8 weeks of taking CP101. 

CP101 is a microbiome therapy. The microbiome is the community of organisms that live in the intestinal tract.
The PRISM4 study is testing a new investigational therapy called CP101.
In a recent study, participants with recurrent C. diff who received CP101 after completing a round of antibiotics were significantly less likely to experience another episode of C. diff, compared to participants who received antibiotics alone. In the study, 74.5% of participants who received CP101 achieved a clinical cure, meaning they did not experience a recurrence of C. diff within 8 weeks of taking CP101. 

CP101 is a microbiome therapy. The microbiome is the community of organisms that live in the intestinal tract.

Study Overview

Medicine

The study therapy is a one-time oral dose of pills/capsules (no bowel prep is needed)

Cost

Participate in this study at no charge and reimbursement for travel costs to and from the study site will be provided

Healthcare

Participants will receive care and close monitoring from an experienced team of healthcare providers dedicated to fighting C. diff

Who can participate?

This study is for adults (18+)*:

Who have recurrent (repeated)
C. diff infection

Who are taking, or are about to start, a course of antibiotics to treat their most recent C. diff infection

*To enter the study, other criteria will also apply.

Are you a good fit for this study?

Find a Study Site